Genetesis, a market leading biomagnetic imaging company, has announced that recent data collected in clinical study with the company’s lead product, CardioFlux was selected for abstract presentations at this year’s American College of Emergency Physicians (ACEP) Scientific Assembly later this month and at American Heart Association (AHA) Scientific Sessions in November.
American College of Emergency Physicians (ACEP) Research Forum:
Title: Detection of Acute Coronary Syndrome by Magnetocardiography
Date and Time: Tuesday, October 26, 2021 at 11:00 a.m. ET
Session Name: RF 18 Abstract Session: Cardiovascular (ACS and non-ACS)
Session Type: Oral Abstract Session
Presenter: Sharon Mace, MD, FACEP, FAAP, Principal Investigator of ACCMED, Emergency Medicine Physician at Cleveland Clinic
Abstract #: 1145
American Heart Association (AHA) Scientific Sessions:
Title: A Novel Way to Predict Obstructive Coronary Artery Disease Requiring Revascularization: The Use of Magnetocardiography
Date: Saturday, November 13 – Monday, November 15, 2021
Session Name: Health Tech Posters II
Session Type: Abstract Poster Presentation
Presenter: Nicholas Coriasso, DO, Cardiology Fellow (PGY5) at Ascension St. John Hospital
Abstract #: 10642
About Genetesis
Genetesis, Inc. is a medical imaging company focused on redefining the way myocardial ischemia and coronary artery disease are detected. By combining CardioFlux, our noninvasive biomagnetic imaging technology, with our proprietary cloud-based web services and machine-learning capabilities, we seek to become the standard of care for diagnosis of cardiovascular disease in the outpatient and acute care settings. Genetesis was founded in 2013 and is based in Mason, Ohio. For more information, visit https://genetesis.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211019005066/en/
Source: Genetesis
View this news release online at:
http://www.businesswire.com/news/home/20211019005066/en
